Published online August 21, 2006
PEDIATRICS Vol. 118 No. 3 September 2006, pp. e833-e838 (doi:10.1542/peds.2005-2053)

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Request Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lubrano, R. Articles by Romero, S. Search for Related Content PubMed PubMed Citation Articles by Lubrano, R. Articles by Romero, S. Related Collections Therapeutics & Toxicology Social Bookmarking                         What's this?

ARTICLE

Renal and Cardiovascular Effects of Angiotensin-Converting Enzyme Inhibitor Plus Angiotensin II Receptor Antagonist Therapy in Children With Proteinuria

Riccardo Lubrano, MD^a, Francesca Soscia, MD^a, Marco Elli, MD^b, Flavia Ventriglia, MD^a, Claudia Raggi, MD^a, Elisabetta Travasso, MD^a, Simona Scateni, MD^a, Valeria Di Maio, MD^a, Paolo Versacci, MD^a, Raffaele Masciangelo, MD^c and Stefano Romero, MD^a

^a Departments of Pediatrics
^c Experimental Medicine and Pathology, University of Rome "La Sapienza," Rome, Italy
^b Department of Clinical Sciences "Ospedale Luigi Sacco," University of Milan, Milan, Italy

OBJECTIVE. We investigated whether the combination of an angiotensin-converting enzyme inhibitor and an angiotensin II type 1 receptor antagonist offers better control of proteinuria and cardiovascular parameters without causing adverse side effects.

METHODS. We enrolled 10 children (mean age: 12.3 ± 4.06 years) with proteinuria resulting from chronic renal diseases of various causes. The study consisted of 2 phases, 3 months each, for an overall 6-month observation time. During phase 1 (3 months), each child was assigned randomly to treatment with either an angiotensin-converting enzyme inhibitor or an angiotensin II type 1 receptor antagonist alone. During phase 2, each child was advanced to combination therapy with the addition of an angiotensin II type 1 receptor antagonist or an angiotensin-converting enzyme inhibitor, respectively. Renal function tests, echocardiography, and 24-hour ambulatory blood pressure monitoring were performed at the beginning of the study (time 0), at 3 months (time 1), and at 6 months (time 2).

RESULTS. At time 2, proteinuria (change: –80.21 ± 10.75%), interventricular septum index (change: –13.63 ± 18.64%), posterior wall of the left ventricle index (change: –30.71 ± 20.32%), and left ventricular mass index (change: –28.33 ± 24.44%) were reduced significantly, compared with time 0 and time 1. No untoward side effects were detected during the study.

CONCLUSIONS. In the short term, the combination of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists for children with proteinuria of renal origin reduced proteinuria significantly, compared with baseline or either drug alone. Furthermore, echocardiographic studies gave evidence of reduction of left ventricular hypertrophy. Additional studies are needed to evaluate long-term results.

---

Key Words: chronic kidney disease • proteinuria • left ventricular hypertrophy • angiotensin-converting enzyme inhibitors • angiotensin II receptor antagonist

Abbreviations: ACE—angiotensin-converting enzyme • AT₁—angiotensin II type 1 • IVS—interventricular septum • LVM—left ventricular mass • PW—posterior wall of the left ventricle • GFR—glomerular filtration rate

---

Accepted Mar 29, 2006.

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?